XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.3

Note 6 - Goodwill and Intangible Assets, Net

6 Months Ended

Sep. 30, 2023

Notes to Financial Statements

Goodwill and Intangible Assets Disclosure [Text Block]

Note 6. Goodwill and Intangible Assets, Net

Intangible assets, the significant majority of which are finite-lived, consisted of the following:

		September 30, 2023												March 31, 2023
		Gross Carrying Amount				Accumulated Amortization				Net Carrying Amount				Gross Carrying Amount				Accumulated Amortization				Net Carrying Amount
Customer relationships		$	231,543			$	(94,486	)		$	137,057			$	238,247			$	(86,058	)		$	152,189
Intellectual property			66,576				(23,160	)			43,416				65,950				(19,550	)			46,400
Other intangibles			24,437				(7,230	)			17,207				24,793				(6,567	)			18,226
Total		$	322,556			$	(124,876	)		$	197,680			$	328,990			$	(112,175	)		$	216,815

Amortization expense for finite-lived intangible assets acquired in a business combination was as follows:

		Three Months Ended September 30,								Six Months Ended September 30,
		2023				2022				2023				2022
Amortization in cost of revenues		$	1,756			$	1,691			$	3,484			$	3,399
Amortization in general and administrative			5,429				5,415				10,921				11,027
Total		$	7,185			$	7,106			$	14,405			$	14,426

For the following fiscal years ending March 31, amortization expense is estimated as follows:

Remainder of 2024		$	13,803
2025			26,523
2026			25,765
2027			25,270
2028			24,825

The change in the carrying amount of goodwill was as follows:

		Sterilization and Disinfection Control				Clinical Genomics				Biopharmaceutical Development				Calibration Solutions				Total
March 31, 2023		$	29,559			$	135,811			$	83,857			$	37,217				286,444
Effect of foreign currency translation			(201	)			(180	)			(3,612	)			(24	)			(4,017	)
Measurement period adjustment - Belyntic Acquisition			-				-				841				-				841
September 30, 2023		$	29,358			$	135,631			$	81,086			$	37,193			$	283,268

Goodwill in the Biopharmaceutical Development division related to the Belyntic acquisition is tax deductible.

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureTextBlockAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for goodwill and intangible assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 350
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//350/tableOfContent

+ Details

Name:	us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration